[ARGX] argenx Thesis 2026: Vyvgart Indication Expansion Drives FcRn Franchise Leadership

Key Takeaways

• argenx SE (NASDAQ: ARGX) FY2025 revenue ~$3.0-3.4B (+50-65% YoY) with adj. EPS ~$3.50-5.00 reflecting continued Vyvgart (efgartigimod) franchise expansion across generalized myasthenia gravis (gMG) + chronic inflammatory demyelinating polyneuropathy (CIDP) + selected post-2024 immune thrombocytopenia (ITP) BLA submission + selected post-2025 multiple selected various indications under continued CEO Tim Van Hauwermeiren (~17-year tenure since 2008 founding; ex-J&J + ex-Innogenetics + ex-Stallergenes + ~25-year industry career; co-founder + chemical engineer by training; selected longest-tenured argenx founder-CEO).
• Vyvgart (efgartigimod) franchise leadership: $3.0-3.4B aggregate revenue FY2025 (+50-65% YoY); first-in-class neonatal Fc receptor (FcRn) antagonist; selected approved indications include generalized myasthenia gravis (gMG; FDA approval December 2021) + CIDP (FDA approval June 2024); selected post-2024 ITP BLA submission + post-2025 anti-AChR Ab+ ocular myasthenia gravis (OMG) + selected various pivotal trial readouts; selected ~$10-15B+ peak sales potential aggregate.
• IV + SC formulation expansion: Vyvgart IV (intravenous) + Vyvgart Hytrulo (subcutaneous) selected ~50-60% Hytrulo mix FY2025 driving patient-friendly self-administered subcutaneous formulation adoption + ~$0.10-0.20 incremental annual EPS contribution; FY2026 catalyst: continued Hytrulo mix expansion toward ~60-70%.
• Capital structure: selected ~$3.5-4B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + R&D investment); selected ~$1.0-1.2B annual R&D spend supporting selected ~10+ pivotal trials + selected various pipeline; investment-grade B1/B+ credit rating (post-2024 upgrade); FY2026 catalyst: continued FCF positive trajectory + selected potential pipeline indication readouts.

Company Background

argenx SE (NASDAQ: ARGX) is a global immunology biotech leader with FY2025 revenue ~$3.0-3.4B (+50-65% YoY) and adj. EPS ~$3.50-5.00 reflecting continued Vyvgart (efgartigimod) franchise expansion across generalized myasthenia gravis (gMG) + CIDP + selected post-2024 ITP BLA submission + selected post-2025 multiple selected various indications. argenx focuses on developing first-in-class antibody therapies for selected severe autoimmune diseases via SIMPLE Antibody platform + selected various proprietary technologies. The company employs ~1,500+ globally with operations across drug development + commercialization in US + EU + Japan + selected various.

Founded 2008 in Breda Netherlands by Tim Van Hauwermeiren + Hans de Haard + Torsten Dreier + selected various Innogenetics + Stallergenes alumni as Crucell-Belgium spinout (~17-year heritage); selected post-2010 Belgium incorporation + selected post-2014 Euronext Brussels IPO; selected post-May 2017 NASDAQ listing; selected post-December 2021 first FDA approval for Vyvgart in generalized myasthenia gravis (gMG) + selected post-2022 EU + Japan approvals; selected post-June 2023 Vyvgart Hytrulo (subcutaneous formulation) FDA approval; selected post-June 2024 FDA approval for Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) — selected first new CIDP treatment in 30+ years.

Headquartered in Amsterdam Netherlands; ~1,500+ employees globally with ~$3.0-3.4B revenue. Single primary product franchise: Vyvgart (efgartigimod) selected first-in-class neonatal Fc receptor (FcRn) antagonist. Geographic mix: US 70-75% revenue ($2.1-2.55B; selected primary commercialization market), EU 15-20% ($0.45-0.6B; selected via direct commercialization), Japan 5-7% ($0.15-0.25B; selected via direct commercialization), Other 3-5% ($0.10-0.20B; selected various international + selected partner markets).

CEO Tim Van Hauwermeiren since 2008 founding (~17-year tenure as co-founder + CEO; selected longest-tenured argenx founder-CEO continuing); Van Hauwermeiren co-founder + chemical engineer by training + ex-Johnson & Johnson + ex-Innogenetics + ex-Stallergenes + ~25-year industry career; CFO Karen Massey (since post-2024; ex-AstraZeneca + ex-Allergan + ~25-year industry career); CSO Hans de Haard (co-founder + ex-Innogenetics).

Vyvgart Franchise Leadership

Vyvgart (efgartigimod) franchise represents selected primary growth driver:

• FY2024 revenue: ~$2.2B (+100%+ YoY)
• FY2025 revenue: $3.0-3.4B (+50-65% YoY)
• Approved indications: gMG (FDA approval December 2021) + CIDP (FDA approval June 2024)
• First-in-class FcRn antagonist: selected unique mechanism reducing pathogenic IgG autoantibodies via FcRn blockade
• gMG: ~$1.5-2B aggregate revenue FY2025; ~10,000+ US patients on therapy
• CIDP: ~$0.8-1.2B aggregate revenue FY2025 (post-June 2024 FDA approval ramp)
• IV + SC formulation: Vyvgart IV (intravenous; original formulation) + Vyvgart Hytrulo (subcutaneous; post-June 2023 FDA approval); selected ~50-60% Hytrulo mix FY2025

FY2026 catalyst: continued gMG + CIDP growth + ITP BLA submission + multiple selected various pivotal trial readouts.

Indication Expansion Pipeline

argenx Vyvgart pipeline expansion across multiple autoimmune indications:

• Immune Thrombocytopenia (ITP): post-2024 BLA submission + post-2025 FDA approval potential; ~$1-2B peak sales potential
• Anti-AChR Ab+ ocular myasthenia gravis (OMG): selected pivotal trial readout post-2025
• Pemphigus: selected pivotal trial readout post-2025
• Sjögren's syndrome: selected pivotal trial readout post-2026
• Lupus nephritis: selected pivotal trial readout post-2026
• Selected various other indications: selected ~10+ pivotal trials covering selected various autoimmune diseases

FY2026 catalyst: continued indication expansion + selected post-2024 ITP BLA + post-2025 multiple readouts + ~$1-3 incremental annual EPS contribution.

SIMPLE Antibody Platform + Pipeline

argenx SIMPLE Antibody platform represents selected proprietary antibody discovery technology:

• SIMPLE Antibody: selected llama-derived antibody discovery platform supporting Vyvgart efgartigimod + selected various pipeline candidates
• ARGX-117 (empasiprubart): selected complement inhibitor for multifocal motor neuropathy (MMN) + selected various complement-driven indications
• ARGX-119: selected MuSK agonist for myasthenia gravis + selected various
• Selected various pipeline: selected ~10+ pipeline candidates covering immunology + selected various

FY2026 catalyst: continued pipeline progression + ARGX-117 + ARGX-119 + selected various.

Risks

• Vyvgart concentration: ~95%+ revenue concentration on Vyvgart franchise; major safety + efficacy + commercial setback risk
• Indication expansion failures: continued ITP + OMG + Pemphigus + Sjögren's + lupus nephritis pivotal trial execution risk
• Pricing pressure: US Inflation Reduction Act Medicare drug price negotiation + EU pricing pressure
• Competitive intensity: UCB Rystiggo + selected various FcRn antagonist competition + selected various autoimmune therapy competition
• Manufacturing scale: continued Vyvgart manufacturing scale-up + selected various supply chain

Key Core Metrics

Market Evaluation

argenx trades at selected ~25-35x FY2026 P/E premium vs Vertex Pharmaceuticals (~25-30x) + Regeneron (~16-20x) + Eli Lilly (~30-40x) reflecting selected continued Vyvgart franchise expansion + selected first-in-class FcRn antagonist mechanism + selected continued ~$10-15B+ peak sales potential + selected continued multiple indication pivotal trial readouts FY2025-2027. Selected re-rating catalysts include: (1) continued Vyvgart gMG + CIDP growth + Hytrulo mix expansion; (2) ITP BLA submission + post-2025 FDA approval potential; (3) post-2025 OMG + Pemphigus pivotal trial readouts; (4) post-2026 Sjögren's syndrome + lupus nephritis pivotal trial readouts; (5) ARGX-117 (empasiprubart) MMN + selected various pipeline progression.

Vyvgart Franchise Leadership Deep Dive

argenx Vyvgart (efgartigimod) franchise represents selected primary differentiation vehicle vs traditional autoimmune therapies (rituximab + IVIG + corticosteroids + selected various). Vyvgart is selected first-in-class neonatal Fc receptor (FcRn) antagonist that selectively reduces pathogenic IgG autoantibodies via FcRn blockade mechanism — selected unique vs traditional B-cell depletion (rituximab) or non-specific immunoglobulin replacement (IVIG). Selected post-December 2021 first FDA approval for Vyvgart in generalized myasthenia gravis (gMG) created selected first targeted FcRn antagonist therapy globally; selected post-June 2023 Vyvgart Hytrulo (subcutaneous formulation) FDA approval supporting patient-friendly self-administered weekly dosing; selected post-June 2024 FDA approval for Vyvgart Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) — selected first new CIDP treatment in 30+ years. Selected $3.0-3.4B aggregate revenue FY2025 (+50-65% YoY) reflects selected continued gMG (~10,000+ US patients on therapy; ~$1.5-2B revenue) + CIDP (post-June 2024 FDA approval ramp; ~$0.8-1.2B revenue) + selected continued Hytrulo subcutaneous formulation mix expansion (~50-60% Hytrulo mix FY2025). Selected ~$10-15B+ aggregate peak sales potential supports continued FY2026-2030 Vyvgart franchise growth across selected ITP + OMG + Pemphigus + Sjögren's + lupus nephritis + selected various autoimmune indication expansion. FY2026 catalyst: continued gMG + CIDP growth + ITP BLA + multiple pivotal trial readouts + ~$1-3 incremental annual EPS.

FY2026 thesis: Vyvgart franchise leadership + ITP + OMG + Pemphigus + Sjögren's + lupus nephritis indication expansion + Hytrulo mix expansion + SIMPLE Antibody pipeline + FCF positive trajectory.